1 day ago
1
koto_feja/E+ via Getty Images
- Zymeworks (NASDAQ:ZYME) said on Friday that the China health regulator has given conditional approval to zanidatamab for the treatment of metastatic HER2-positive biliary tract cancer.
- The approval was secured by Zymeworks’ Asia Pacific partner, BeOne Medicines, under their existing license and collaboration agreement.
English (US) ·